Viatris Inc (VTRS) stock
VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/303% below fair value
$19.63−0.25 (-1.26%)
Close on Nov 20, 2026Market cap $22.55BP/E –Yield 2.45%
Viatris free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Viatris's free cash flow for the twelve months ending Jun 30, 2026 was $1.95B, up 11.6% year over year. For fiscal 2025 it was $1.94B, down 2.0% from the year before. The highest annual figure on record is $2.59B in fiscal 2022.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.94B | -2.0% |
| FY2024 | Dec 31, 2024 | $1.98B | -21.6% |
| FY2023 | Dec 31, 2023 | $2.52B | -2.7% |
| FY2022 | Dec 31, 2022 | $2.59B | +1.3% |
| FY2021 | Dec 31, 2021 | $2.56B | +158.9% |
| FY2020 | Dec 31, 2020 | $988.80M | -37.8% |
| FY2019 | Dec 31, 2019 | $1.59B | -23.9% |
| FY2018 | Dec 31, 2018 | $2.09B | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $329.00M | +97.2% |
| Q1 FY2026 | Mar 31, 2026 | $348.40M | -29.3% |
| Q4 FY2025 | Dec 31, 2025 | $619.30M | +80.9% |
| Q3 FY2025 | Sep 30, 2025 | $658.10M | -12.2% |
| Q2 FY2025 | Jun 30, 2025 | $166.80M | -47.9% |
| Q1 FY2025 | Mar 31, 2025 | $492.90M | -12.7% |
| Q4 FY2024 | Dec 31, 2024 | $342.30M | -15.1% |
| Q3 FY2024 | Sep 30, 2024 | $749.50M | +1.4% |
| Q2 FY2024 | Jun 30, 2024 | $320.30M | -30.0% |
| Q1 FY2024 | Mar 31, 2024 | $564.80M | -38.8% |
| Q4 FY2023 | Dec 31, 2023 | $403.00M | +1041.6% |
| Q3 FY2023 | Sep 30, 2023 | $739.30M | -3.4% |
| Q2 FY2023 | Jun 30, 2023 | $457.30M | -36.4% |
| Q1 FY2023 | Mar 31, 2023 | $923.40M | -14.0% |
| Q4 FY2022 | Dec 31, 2022 | $35.30M | -89.2% |
| Q3 FY2022 | Sep 30, 2022 | $765.10M | -20.7% |
| Q2 FY2022 | Jun 30, 2022 | $718.60M | +52.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.07B | +34.4% |
| Q4 FY2021 | Dec 31, 2021 | $325.70M | – |
| Q3 FY2021 | Sep 30, 2021 | $964.60M | +98.2% |
| Q2 FY2021 | Jun 30, 2021 | $470.10M | +40.3% |
| Q1 FY2021 | Mar 31, 2021 | $799.30M | +222.7% |
| Q4 FY2020 | Dec 31, 2020 | -$80.70M | – |
| Q3 FY2020 | Sep 30, 2020 | $486.80M | – |
| Q2 FY2020 | Jun 30, 2020 | $335.00M | – |
| Q1 FY2020 | Mar 31, 2020 | $247.70M | – |
See a number that looks wrong?